New collaboration expands point-of-care PPID diagnostics

New collaboration expands point-of-care PPID diagnostics

Zomedica and Boehringer Ingelheim Animal Health USA have launched a strategic collaboration that folds Zomedica’s TRUFORMA platform into Boehringer’s idPPID awareness and testing program for horses. Under the March 18, 2026 announcement, participating equine practices can receive no-cost placement of TRUFORMA analyzers, while Boehringer reimburses diagnostic testing performed on the platform using Zomedica’s equine endogenous ACTH and insulin assays; the program also continues reimbursement through Cornell University laboratory testing. The companies say the goal is to speed earlier detection, treatment, and monitoring of pituitary pars intermedia dysfunction, or PPID, in horses. (accessnewswire.com)

Why it matters: For equine veterinarians, the collaboration could reduce one of the biggest practical barriers to PPID workups: waiting on outside-lab endocrine results. Independent reporting on the TRUFORMA ACTH assay presented at the 2025 Global Equine Endocrinology Symposium found good overall agreement with a chemiluminescent immunoassay, though the point-of-care test showed a larger negative bias in horses with PPID, underscoring that results still need to be interpreted in clinical context. That matters because current PPID guidance emphasizes combining history, physical exam, and laboratory data, and also recommends assessing insulin dysregulation in all PPID patients. (equimanagement.com)

What to watch: Watch for how quickly equine practices enroll, whether published validation data broaden confidence in stall-side endocrine testing, and how the reimbursement model affects long-term cartridge use beyond the initial program. (accessnewswire.com)